Resources
Webinar: Biofilm Testing - Advanced Models for Real-World Applications
Wednesday, October 8th @ 11 AM ET
Making meaningful progress in designing products with consideration for infection prevention, antimicrobial implants, and advanced wound care requires more than standard antimicrobial assays. Robust biofilm models are essential for recapitulating the complex microbial system and its surrounding matrix.
In this webinar, iFyber will delve into advanced in vitro and ex vivo biofilm test systems, model selection, critical endpoints, and data interpretation.
What this session will cover:
- State-of-the-art Biofilm Models: Explore a range of model systems, including Bottom-of-the-Plate (BOTP), MBEC/peg-type assays, porcine dermal models (PDM), and living human skin explant models. Understand their architecture and how these features impact microbial colonization, matrix development, and antimicrobial penetration.
- Clinically Relevant Skin & Wound Models: Review ex vivo living human viable full-thickness dermal wound models for simulating infection, host response, and wound healing. Assess how variables like tissue viability, host-microbe interaction, and biofilm maturation stage modulate therapeutic efficacy.
- Designing for Relevance and Reproducibility: Key parameters such as inoculum size, strain selection (mono- vs polymicrobial), biofilm maturation time, nutrient/media composition, endpoint readouts (CFU, metabolic, imaging, viability, quorum sensing, etc.), and statistical considerations.
- Interpreting Results & Translational Considerations: Dive into hurdles such as biofilm heterogeneity, matrix interference, differential susceptibility, resistance development, and correlating in vitro/ex vivo findings with in vivo or clinical data. Discussion on regulatory expectations for claims related to biofilm prevention or eradication.
- Case Studies & Applications: Real-world examples from wound care, medical devices (catheters, implantable surfaces), antimicrobial coatings, sterilization processes. Compare how different models reveal unique insights and inform decision-making across product development, quality assurance, and regulatory strategy.
Why You Should Attend
- Understand how preclinical wound care and biofilm models de-risk product development can
- Gain insight into which assay systems best simulate complex wound environments
- Learn how iFyber partners with innovators, delivering rigorous and actionable results
Reserve Your Spot
Gain deeper technical insights into biofilm testing strategies so you can design experiments that are reproducible, clinically relevant, and aligned with regulatory expectations.
Speaker Information
Aaron Strickland
VP of R&D, Co-Founder, iFyber
Aaron is iFyber’s co-founder and Vice President of R&D, with over 20 years of research experience in chemistry, microbiology, molecular biology, and nanotechnology. He directs multidisciplinary teams on corporate and federally funded projects, including work for the NSF, NIH, and multiple branches of the U.S. military. Aaron holds a Ph.D. in chemistry from the University of Wyoming and completed postdoctoral research in microbiology and biotechnology at Cornell University.
About iFyber
iFyber is a contract research organization specializing in microbial control, tissue and biofilm models, analytical assays, and custom testing platforms for life sciences, medical devices, and advanced materials. Our team combines deep expertise in biofilm biology, tissue models, imaging, and quantitative endpoints to deliver data you can trust.